Reference : The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells ...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/83490
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
English
Crisanti, Cecilia [ > > ]
Wallace, Africa [ > > ]
Kapoor, Veena [ > > ]
Vandermeers, Fabian [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Dowling, Melissa [ > > ]
Pereira, Luana [ > > ]
Coleman, Kara [ > > ]
Campling, Barbara [ > > ]
Fridlender, Zvi [ > > ]
Kao, Gary [ > > ]
Albelda, Steven [ > > ]
Aug-2009
Molecular Cancer Therapeutics
American Association for Cancer Research, Inc. (AACR)
8
8
2221-2231
Yes (verified by ORBi)
International
1535-7163
1538-8514
Philadelphia
PA
[en] Lung cancer is the leading cause of cancer deaths in the
United States. Current therapies are inadequate. Histone
deacetylase inhibitors (HDACi) are a recently developed
class of anticancer agents that cause increased acetylation
of core histones and nonhistone proteins leading to
modulation of gene expression and protein activityin -
volved in cancer cell growth and survival pathways.
We examined the efficacyof the HDACi panobinostat
(LBH589) in a wide range of lung cancers and mesotheliomas.
Panobinostat was cytotoxic in almost all 37 cancer
cell lines tested. IC50 and LD50 values were in the
low nmol/L range (4–470 nmol/L; median, 20 nmol/L).
Small cell lung cancer (SCLC) cell lines were among
the most sensitive lines, with LD50 values consistently
<25 nmol/L. In lung cancer and mesothelioma animal
models, panobinostat significantlyde creased tumor
growth byan average of 62% when compared with vehicle
control. Panobinostat was equallye ffective in
immunocompetent and severe combined immunodeficiencymic
e, indicating that the inhibition of tumor growth by
panobinostat was not due to direct immunologic effects.Panobinostat was, however, particularlyeffective in SCLC
xenografts, and the addition of the chemotherapyag ent
etoposide augmented antitumor effects. Protein analysis
of treated tumor biopsies revealed elevated amounts of cell
cycle regulators such as p21 and proapoptosis factors,
such as caspase 3 and 7 and cleaved poly[ADP-ribose] polymerase,
coupled with decreased levels of antiapoptotic
factors such as Bcl-2 and Bcl-XL. These studies together
suggest that panobinostat maybe a useful adjunct in the
treatment of thoracic malignancies, especiallySCLC.
http://hdl.handle.net/2268/83490

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Panobinostat paper- MCR- 2009[1].pdfPublisher postprint602.5 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.